China · Delayed Price · Currency is CNY Guanhao Biotech Statistics
Total Valuation
Guanhao Biotech has a market cap or net worth of CNY 3.74 billion. The enterprise value is 3.64 billion.
| Market Cap | 3.74B |
| Enterprise Value | 3.64B |
Important Dates
The last earnings date was Wednesday, April 29, 2026.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Guanhao Biotech has 265.16 million shares outstanding. The number of shares has increased by 3.00% in one year.
| Current Share Class | 265.16M |
| Shares Outstanding | 265.16M |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | -9.42% |
| Owned by Insiders (%) | 1.87% |
| Owned by Institutions (%) | 6.94% |
| Float | 199.79M |
Valuation Ratios
The trailing PE ratio is 195.59.
| PE Ratio | 195.59 |
| Forward PE | n/a |
| PS Ratio | 9.69 |
| PB Ratio | 7.57 |
| P/TBV Ratio | 7.35 |
| P/FCF Ratio | 226.29 |
| P/OCF Ratio | 87.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 77.13, with an EV/FCF ratio of 220.25.
| EV / Earnings | 185.53 |
| EV / Sales | 9.43 |
| EV / EBITDA | 77.13 |
| EV / EBIT | 166.04 |
| EV / FCF | 220.25 |
Financial Position
The company has a current ratio of 2.00, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.00 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 7.83 |
| Interest Coverage | 5.79 |
Financial Efficiency
Return on equity (ROE) is 1.48% and return on invested capital (ROIC) is 1.91%.
| Return on Equity (ROE) | 1.48% |
| Return on Assets (ROA) | 1.85% |
| Return on Invested Capital (ROIC) | 1.91% |
| Return on Capital Employed (ROCE) | 3.62% |
| Weighted Average Cost of Capital (WACC) | 5.72% |
| Revenue Per Employee | 722,237 |
| Profits Per Employee | 36,714 |
| Employee Count | 535 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.25 |
Taxes
In the past 12 months, Guanhao Biotech has paid 11.43 million in taxes.
| Income Tax | 11.43M |
| Effective Tax Rate | 61.14% |
Stock Price Statistics
The stock price has increased by +6.89% in the last 52 weeks. The beta is 0.29, so Guanhao Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | +6.89% |
| 50-Day Moving Average | 15.17 |
| 200-Day Moving Average | 15.83 |
| Relative Strength Index (RSI) | 39.90 |
| Average Volume (20 Days) | 5,176,360 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guanhao Biotech had revenue of CNY 386.40 million and earned 19.64 million in profits. Earnings per share was 0.07.
| Revenue | 386.40M |
| Gross Profit | 295.75M |
| Operating Income | 22.92M |
| Pretax Income | 18.69M |
| Net Income | 19.64M |
| EBITDA | 43.45M |
| EBIT | 22.92M |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 144.22 million in cash and 129.59 million in debt, with a net cash position of 14.64 million or 0.06 per share.
| Cash & Cash Equivalents | 144.22M |
| Total Debt | 129.59M |
| Net Cash | 14.64M |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | 494.91M |
| Book Value Per Share | 2.28 |
| Working Capital | 154.24M |
Cash Flow
In the last 12 months, operating cash flow was 42.58 million and capital expenditures -26.03 million, giving a free cash flow of 16.55 million.
| Operating Cash Flow | 42.58M |
| Capital Expenditures | -26.03M |
| Depreciation & Amortization | 20.53M |
| Net Borrowing | 5.26M |
| Free Cash Flow | 16.55M |
| FCF Per Share | 0.06 |
Margins
Gross margin is 76.54%, with operating and profit margins of 5.93% and 5.08%.
| Gross Margin | 76.54% |
| Operating Margin | 5.93% |
| Pretax Margin | 4.84% |
| Profit Margin | 5.08% |
| EBITDA Margin | 11.25% |
| EBIT Margin | 5.93% |
| FCF Margin | 4.28% |
Dividends & Yields
Guanhao Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.25% |
| Buyback Yield | -3.00% |
| Shareholder Yield | -3.00% |
| Earnings Yield | 0.52% |
| FCF Yield | 0.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 16, 2015. It was a forward split with a ratio of 2.
| Last Split Date | Apr 16, 2015 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |